secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001437749-24-010359
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros posts Q4 net loss $9.1M, secures $115.5M from OMIDRIA royalty sale
-------------------------------------------------------------------------

- Q4 2023 net loss $9.1M ($0.15/sh) vs Q3 loss $37.8M; full-year net loss $117.8M ($1.88/sh) vs prior-year net income $47.4M.
- Amended OMIDRIA royalty deal with DRI: received $115.5M; DRI gets all U.S. royalties through 2031; Omeros retains ex-U.S. & post-2031 global royalties; potential $55M milestones.
- Cash and investments $171.8M at Dec 31, 2023; plus $115.5M from DRI in Feb 2024; expects ~$230M at Mar 31, 2024 after share repurchases.
- Narsoplimab BLA resubmission in TA-TMA still under FDA discussion; unable to estimate timing for submission or approval.
- OMS906 Phase 2 trials in PNH fully enrolled; positive interim data; Phase 3 targeted late 2024; OMS1029 Phase 1 multiple-ascending dose completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774924010359/0001437749-24-010359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774924010359/omer20231204_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-010359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer